Cargando…
Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice
Mucopolysaccharidosis II (MPS II), a lysosomal storage disease caused by mutations in iduronate-2-sulfatase (IDS), is characterized by a wide variety of somatic and neurologic symptoms. The currently approved intravenous enzyme replacement therapy with recombinant IDS (idursulfase) is ineffective fo...
Autores principales: | Morimoto, Hideto, Kida, Sachiho, Yoden, Eiji, Kinoshita, Masafumi, Tanaka, Noboru, Yamamoto, Ryuji, Koshimura, Yuri, Takagi, Haruna, Takahashi, Kenichi, Hirato, Tohru, Minami, Kohtaro, Sonoda, Hiroyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116601/ https://www.ncbi.nlm.nih.gov/pubmed/33508431 http://dx.doi.org/10.1016/j.ymthe.2021.01.027 |
Ejemplares similares
-
A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II
por: Sonoda, Hiroyuki, et al.
Publicado: (2018) -
Enzyme replacement with transferrin receptor-targeted α-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice
por: Kida, Sachiho, et al.
Publicado: (2023) -
Pathogenic Roles of Heparan Sulfate and Its Use as a Biomarker in Mucopolysaccharidoses
por: Minami, Kohtaro, et al.
Publicado: (2022) -
Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II
por: Yamamoto, Ryuji, et al.
Publicado: (2021) -
Dose-dependent effects of a brain-penetrating iduronate-2-sulfatase on neurobehavioral impairments in mucopolysaccharidosis II mice
por: Morimoto, Hideto, et al.
Publicado: (2022)